Episode Details

In this healthcare podcast, I am speaking with Cora Opsahl, who directs the 32BJ Health Fund. This is the second conversation I'm having with Cora (last one was EP372), but these two conversations are not really linear—so listen in whatever order you want to.

Important to know about Cora's background, in previous roles, she has worked deep in the inner sanctums of the healthcare industry. So, she came to 32BJ armed with a BS meter that's finely tuned, which is, as I said last week, an unfortunately essential skill for anyone trying to help patients and members relying on them to successfully navigate the healthcare industry.

Here's a pivotal fact: 56% of total spend at the 32BJ Health Fund goes to hospitals. So, from a "making the juice worth the squeeze" perspective, focusing on hospital prices can have a lot of impact.

This is doubly true because of the seriously huge price variations for the same exact types of services at different hospitals, even in the same local market. Because the 32BJ Health Fund demands and gets all of its own data, it can actually run reports and see the impact and nuances of hospital spend very clearly—unlike, frankly, the majority of employers and unions who have zero clue this is all going on behind their backs because they think some other party is actually the fiduciary and not them, which is false, of course.

So, let's just linger on this really high hospital prices that are various across a market for one moment. Here's a Tweet from Rik Renard: "The price of CABG [coronary artery bypass graft] varies more than 10-fold across US hospitals (ranging from $44,824 to $448,038). There was no evidence to suggest that hospitals that charge higher prices provide a better quality of care."

WHAT?! An employer could pay $44,000, or it could pay $448,000. Seriously? This is why we can't have nice raises—because some employer spent $400,000 not on raises but on overpriced hospital services. Ugh … so frustrating. When employers, almost willfully at this juncture, turn a blind eye to all of this because they think it might be disruptive, meanwhile they're worrying about employee retention and trying to figure out how to give raises. Okay, well, here's a suggestion: Get your healthcare house in order and then you'll have enough money for raises, but that aside …

In the New York City market, 32BJ used all of the data that we talked about in the last episode (EP372). They used all of that data to deduce, quite crisply, that NewYork-Presbyterian is really, really expensive—even in comparison to other expensive health systems in the New York metro area.

Furthermore, the Fund realized that it could not be sustainable without tackling the challenge of hospital prices. As Cora Opsahl says, "You can't reduce spend by benefit design alone." Which reminded me of that famous quote by Uwe Reinhardt, "It's the prices, stupid." Which, of course, reminded me of what David Contorno has said a million times, "You can't pay less for healthcare unless you pay less for healthcare."

I can't overemphasize these points and their impact on employers and workers. It's really hard to be competitive in the global marketplace when shelling out an extra $400,000 here and an extra whatever tens of thousand dollars there for fringe benefits that do not actually add any value from the workers' standpoint and/or confer any additional health. This is just blatantly throwing money away.

So, there's gonna be a few health system peeps listening here who will reflexively mutter under their breath a sentence including the terminology "razor-thin operating margin." It must be an AHA talking poi